Abstract
A novel strategy for anti-viral intervention of hepatitis B virus (HBV) through the disruption of the proper folding1 and transport2 of the hepadnavirus glycoproteins is described. Laboratory reared woodchucks chronically infected with woodchuck hepatitis virus (WHV) were treated with N-nonyl-deoxynojirimycin (N-nonyl-DNJ), an inhibitor of the endoplasmic reticulum (ER) α-glucosidases. The woodchucks experienced significant dose dependent decreases in enveloped WHV, resulting in undetectable amounts in some cases. The reduction in viremia correlated with the levels of hyperglucosylated glycan in the serum of treated animals. This correlation supports the mechanism of action associated with the drug and highlights the extreme sensitivity of the virus to this type of glycan inhibitor1,2. At N-nonyl-DNJ concentrations that prevented WHV secretion, the glycosylation of most serum glycoproteins appeared unaffected, suggesting great selectivity for this class of therapeutics. Indeed, this may account for the low toxicity of the compound over the treatment period. We provide the first evidence that glucosidase inhibitors can be used in vivo to alter specific steps in the N-linked glycosylation pathway and that this inhibition has anti-viral effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mehta, A., Lu, X., Block, T.M., Blumberg, B.S. & Dwek, R.A. Hepatitis B virus envelope proteins vary drastically in their sensitivity to glycan processing. Proc. Natl. Acad. Sci. USA 94, 1822–1827 (1997).
Lu, X. et al. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci USA 94, 2380–2385 (1997).
Sherker, A. & Marion, P. Hepadnaviruses and hepatocellular carcinoma. Ann Revs. Microb. 45, 475–508 (1991).
Tipples, G.A. et al. Mutations in the HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24, 714–717 (1996).
Tennant, B.C. & Gerin, J.L. The woodchuck model of hepatitis B virus infection. In: The Liver: Biology and pathobiology. 3rd edition. Eds. Aries, I.M. et al. Raven press, Publisher (NY, NY) pp. 1455–1466 (1994).
Hoofnagle, J.H. & DiBisceglie, A.M. Drug Therapy: The treatment of chronic viral hepatitis. New Engl. J. Med. 336, 347–356 (1997).
Wong, D.C., Shi, J.W.K., Purcell, R.H., Gerin, J.L. & London, W.T. Natural and experimental infection of woodchucks with woodchuck hepatitis virus, as measured by new, specific assays for woodchuck hepatitis surface antigen and antibody. J. Clin. Microb. 15, 484–490 (1982).
Lu, X., Mehta, A., Butters, T., Dwek, R. & Block, T. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virol. 213, 660–665 (1995).
Cullen, J.M. et al. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethly)-1,3-oxathiolan-5-yl] cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicro. Agents Chemo. 41, 2076–2082 (1997).
Nowak, M.A. et al. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93, 4398–4402 (1996).
Ueda, K., Tsurimoto, T. & Matsubara, K. Three Envelope Proteins of Hepatitis B virus: Large S, Middle S, and Major S needed for the formation of Dane particles J. Virol. 65, 3521–3529 (1991).
Seifer, M., Heermann, K.H. & Gerlich, W.J. Replication of hepatitis B virus in transfected nonhepatic cells. Virol. 179, 300–311 (1990).
Wei, Y., Tavis, J.E. & Ganem, D. Relationship between viral DNA synthesis and virion envelopment in hepatitis B virus. J. Virol. 70, 6455–6458 (1997).
Abe, K., Kurata, T. & Shikata, T. Localization of woodchuck hepatitis virus in the liver. Hepatology 8, 88–92 (1988).
Moore, S.E. & Spiro, R.G. Demonstration that Golgi endo—D-mannosidase provides a glucosidase independent pathway for the formation of complex N-linked oligosaccharides of glycoproteins. J. Biol. Chem. 265, 13104–13112 (1990).
Werr, M. & Prange, R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J. Virol. 7, 778–782
Jacob, G.S. Glycosylation inhibitors in biology and medicine. Curr. Opin Struct. Biol. 5, 605–611 (1995).
Karpas, A. et al. Amino sugar derivatives as potential anti-HIV agents . Proc. Natl. Acad. Sci. USA 85, 9229–9233 (1988).
Fontana, R.J. & Lok, A.S.F. Combination therapy for chronic hepatitis B. Hepatology 26, 234–236 (1997).
Korba, A.B. et al. Liver-targeted antiviral nucleosides: Enhanced antiviral activity of phosphatidyl-dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo . Hepatology 23, No.6 958–963 (1996).
Lee, W.M. et al. Antibodies to polymerized albumin in woodchuck hepatitis virus infection. Viral Immuno. 6, 13–19 (1993).
Guile, G.R., Rudd, P., Wing, D., Prime, S.B. & Dwek, R.A. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 240, 210–226 (1996).
Rudd, P.M. et al. Oligosaccharide Sequence Technology. Nature 388, 205–208 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Block, T., Lu, X., Mehta, A. et al. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4, 610–614 (1998). https://doi.org/10.1038/nm0598-610
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0598-610